Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
about
LEGER: knowledge database and visualization tool for comparative genomics of pathogenic and non-pathogenic Listeria speciesImmunotherapy for brain cancer: recent progress and future promiseVaccines: the Fourth CenturyCan biowarfare agents be defeated with light?Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responsesVaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A VirusProspects for a novel ultrashort pulsed laser technology for pathogen inactivation.Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Protective immunity to Listeria monocytogenes infection mediated by recombinant Listeria innocua harboring the VGC locus.T cell and APC dynamics in situ control the outcome of vaccinationPrior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV.A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.Directed antigen delivery as a vaccine strategy for an intracellular bacterial pathogen.A novel vaccine targeting Fusobacterium nucleatum against abscesses and halitosis.Proteomics integrated with Escherichia coli vector-based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase-like protein of Propionibacterium acnes.Acinetobacter baumannii: emergence of a successful pathogenAttenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cellsCytosolic entry controls CD8+-T-cell potency during bacterial infection.In vitro properties of a Listeria monocytogenes bacteriophage-resistant mutant predict its efficacy as a live oral vaccine strain.Detection of prokaryotic mRNA signifies microbial viability and promotes immunity.Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.Global challenge of multidrug-resistant Acinetobacter baumanniiA novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.Clinical development of Listeria monocytogenes-based immunotherapies.Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and VaccinationOntology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responsesConstitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strainsLive attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys.A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer.KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.Listeria monocytogenes: a promising vehicle for neonatal vaccination.Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthraxPromises and challenges for the development of Listeria monocytogenes-based immunotherapies.NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.Biotechnological applications of Listeria's sophisticated infection strategies.
P2860
Q25257921-53A3231E-9A1B-4F63-AB11-43972C20B168Q27015881-F1922036-4EBD-483B-B51A-B6E397FA4401Q27490454-87684F70-242D-4888-BB79-C66A135A8BD6Q28396096-EFF98121-3BA2-4B3A-92FD-5C8DCD8E7C1EQ28740555-E7AE5F33-0F70-4FD6-AD9C-E2C60C0A6AA5Q30401849-461C0298-BA5F-42BD-BB79-701D53883D7DQ30460718-8DA10653-FEE0-4BC0-ADBF-4103263A08A0Q33633839-2CD26964-B68E-4CD4-9F7B-85CD63EF6653Q34247324-2111A0B7-2D44-4EBA-AEC3-103112C6854AQ34381612-7BBC59A9-527C-4608-8CC6-B60F99875586Q34552488-3BB2048D-79DF-4C5E-92F7-A34792AAC928Q34575993-C1498AB0-E481-42EA-84F6-E30EFE196AF8Q34596940-5D0E51B4-5DC1-4927-9434-398EE57AC72AQ34670690-F0AE9033-ADEC-47D1-907E-0AA6C1FA2461Q34759942-26815B2D-2D7E-412E-A225-19C4FE3D7A48Q34795807-E8C3F425-63A5-4871-B79B-FD7A4B762C16Q34871958-6037B57D-0CFC-4AD9-AB11-94898EF05035Q35024249-A39FAFDC-5BAF-42AA-8D47-78024443E6AFQ35204687-E6E38BBD-4090-40CB-9FE4-D0B87FA931A9Q35217477-E07B43D1-8EF6-4D4D-8AB7-51FD83B05091Q35598094-F849A99E-BB55-44FE-923F-4A5FCEED0F8AQ35789153-7AF2C18A-950B-4AE5-9277-05985C344F2DQ35867177-0594691E-9F51-4688-867B-F2AA844501CBQ36095081-CBFAB7E4-ABFF-4135-ACE4-E4C0B9A6BD84Q36328022-532416BA-5913-4103-9175-72E1CDEE1288Q36600365-7D40E710-07FD-497A-B9B8-8B9B51B226FDQ36615924-6A7BC819-382E-4762-BEA8-159FCEFBAB70Q36781474-B604B8CA-8B14-4E6A-A504-1D240ADE4FB9Q36803269-21D4574D-B1CD-410A-B513-C60A61516282Q36804198-870D768A-6A98-4A4D-95F3-45E8F7F82654Q36841404-C1F1BC6A-1C82-4BFB-8A5D-4EDDFF97AB2FQ36883886-C24E041B-A700-45E3-AD4F-BEBE0A2A2388Q36884247-53E356B3-5F09-4564-AD55-7D123DB4935AQ36964813-AE68E867-20CE-42DD-8CD2-CA922CFEA767Q36977730-15A2A35A-AC7E-43EA-9651-96CEDD6482F7Q37125549-A10A5343-9812-442B-A31C-EA5DB390AFC1Q37145046-72FC6E66-3B5E-4BE1-AFF5-DF4375373CFEQ37259634-781E36B5-BF81-4010-BE0A-E19E1F8C51E9Q37262370-685BF136-EE61-40C5-AA45-81ECF69DA5F9Q37273327-7EAD2AEB-C702-463C-A055-C29C9A7B6E3F
P2860
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Killed but metabolically activ ...... onses and protective immunity.
@en
Killed but metabolically activ ...... onses and protective immunity.
@nl
type
label
Killed but metabolically activ ...... onses and protective immunity.
@en
Killed but metabolically activ ...... onses and protective immunity.
@nl
prefLabel
Killed but metabolically activ ...... onses and protective immunity.
@en
Killed but metabolically activ ...... onses and protective immunity.
@nl
P2093
P2860
P356
P1433
P1476
Killed but metabolically activ ...... onses and protective immunity.
@en
P2093
A A Herskovits
A Sampson-Johannes
A Stassinopoulos
D A Portnoy
D G Brockstedt
H G Archie Bouwer
J E Hearst
P2860
P2888
P304
P356
10.1038/NM1276
P407
P577
2005-07-24T00:00:00Z